Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : GlaxoSmithKline Biologicals
Femme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 5 ans
Safety and reactogenicity study of GlaxoSmithKline (GSK) Biologicals’ investigational respiratory syncytial virus (RSV) vaccine (GSK3003891A) in healthy women
To evaluate the reactogenicity and safety of a single dose of the investigational RSV vaccine in healthy non-pregnant women during the study period.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 5 ans
Safety and immunogenicity study of GSK Biologicals’ Quadrivalent Influenza Vaccine (GSK2321138A) manufactured with a new process in adults and children
•To describe the safety of 1 dose of FLU D-QIV vaccine produced by the IP and 1 dose of FLU D-QIV vaccine produced by the LP in terms of solicited (7 days after vaccination) and unsolicited adverse ev...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 5 ans
A Phase II, open (partially double-blind), randomized, controlled dose-range study to evaluate the immunogenicity, reactogenicity and safety of four different formulations of GlaxoSmithKline (GSK) Biologicals’ meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine versus MenC-CRM197 conjugate vaccine or MENCEVAX™ ACWY when given as one dose to children aged 12 to 14 months and 3 to 5 years old
Based on the immune response induced one month post vaccination, to select the best of four different formulations of GSK Biologicals’ MenACWY-TT conjugate vaccine when given as one single dose to hea...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 5 ans
A phase II, multicentre booster study to evaluate booster vaccination with GSK Biologicals’ 10-valent pneumococcal conjugate vaccine or to evaluate the immune memory following the administration of a single dose of 23-valent plain polysaccharide vaccine in healthy children, previously vaccinated in infancy in the primary study 11PN-PD-DIT-002 (103488)
To assess the immunological memory following primary vaccination with either GSK Biologicals’ selected 3µg 18C-TT containing 11Pn-PD-DiT vaccine formulation or the 11Pn-PD vaccine or Prevenar™, throug...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 5 ans
Immunogenicity and safety study of GlaxoSmithKline Biologicals’ Infanrix hexa™ vaccine in healthy infants in India
To assess the immunological response to the study vaccine in terms of seroprotection status for diphtheria, tetanus, polio, hepatitis B (HB) and Haemophilus influenza type b (Hib) anti-gens, and in te...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 5 ans
A phase I/II, open, controlled study in order to evaluate the reactogenicity and the immunogenicity of GlaxoSmithKline Biologicals influenza candidate vaccine containing the adjuvant AS25 (FluAS25) in an elderly population aged over 65 years (>65 years-old) previously vaccinated in 2004 with the same candidate vaccine in FLUAS25-001 clinical trial. For immunogenicity and safety evaluations, Fluarix™ (known as alpha-Rix™ in Belgium)vaccine will be used as reference
To evaluate the safety and reactogenicity of a revaccination with adjuvanted vaccine FluAS25 during 21 days following the intramuscular administration of the vaccine. Fluarix will be used as reference...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 5 ans
Immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ Human Papillomavirus (HPV) 580299 vaccine in healthy Chinese female subjects
•To demonstrate the non-inferiority of HPV immune response at one month post-dose 3 in Chinese female subjects aged 9-17 years from the current study versus Chinese women aged 18-25 years enrolled in ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 5 ans
Safety and immunogenicity study of GSK Biologicals’ candidate tuberculosis vaccine (692342) when administered to healthy infants
•To evaluate the safety and reactogenicity of one or two doses of the TB vaccine candidate (M72/AS01E) when given to healthy infants concomitantly with the Expanded Programme on Immunisation (EPI) reg...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme Max 99 ans
GlaxoSmithKline Biologicals S.A
MAJ Il y a 5 ans
Testing of the liquid and lyophilized formulation of a vaccine on non-pregnant women that are 18 to 40 years old to asess its safety and the protection it gives from blood poisoning caused by a bacterium
Immunogenicity Objectives To demonstrate the equivalence of the liquid GBS trivalent vaccine formulation to the lyophilized GBS trivalent vaccine formulation for serotypes Ia, Ib, and III, when admin...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 5 ans
Combined Study – Phase 3b MenB Long Term Persistence in Adolescents
•To assess serum bactericidal activity at approximately 4 to 7.5 years following a 2 dose primary series (persistence) compared to serum bactericidal activity at baseline in vaccination-naïve subjects...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant